Abstract: The present invention relates to a novel naphthyridinone derivative compound, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a stereoisomer thereof, which are each relevant to a compound for inhibiting ENPP1, a composition for inhibiting ENPP1, and a method for inhibiting ENPP1.

Abstract: A method for counting coughs is provided. The method includes acquiring a plurality of onset signals from the sound signal, wherein the onset signal has a predetermined time length; acquiring a plurality of spectrograms corresponding to each of the plurality of onset signals; determining whether each of the acquired plurality of spectrograms represents a cough using a cough determination model; and calculating a number of coughs included in the sound signal based on a time point of a cough signal. The cough signal is an onset signal corresponding to one spectrogram determined to represent the cough. When a time interval between a first time point of a first cough signal and a second time point of a second cough is within a reference time interval, the first cough signal and the second cough signal are regarded as one cough signal at the first time point.

Abstract: A display device includes first emission areas, second emission areas, and third emission areas for respectively emitting colors of light, first pixel electrodes, second pixel electrodes, and third pixel electrodes overlapping the first emission areas, the second emission areas, and the third emission areas, respectively, first data lines respectively connected to the first pixel electrodes, and overlapping some of the first emission areas, second data lines respectively electrically connected to the second pixel electrodes, overlapping some others of the first emission areas, and being spaced apart from the first data lines, and a demultiplexer configured to divide and output corresponding portions of an input, which is received from one fan-out line, to the first data lines and the second data lines.

Abstract: The present invention relates to a novel benzotriazole derivative compound, a tautomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a stereoisomer thereof, which are related to a compound for inhibiting ENPP1, a composition for inhibiting ENPP1, and a method for inhibiting ENPP1.

Abstract: A multilayer capacitor includes a capacitor body having first to sixth surfaces, including a plurality of first and second dielectric layers and a plurality of internal electrodes stacked; and first and second external electrodes. The internal electrode includes first and second internal electrodes, a first floating electrode disposed between the first and second internal electrodes on the first dielectric layer, and second and third floating electrodes disposed on the second dielectric layer. The second floating electrode overlaps a portion of the first internal electrode and a portion of the first floating electrode, and the third floating electrode overlaps a portion of the second internal electrode and a portion of the first floating electrode. a/L is 0.113 or more, in which L is a length of the capacitor body, and a is a distance between the first floating electrode and the first or second internal electrodes.

Abstract: A composition suitable for preventing or treating an inflammatory disease is disclosed. The composition contains zinc finger protein with KRAB and SCAN domains 8 (Zkscan8) protein, which has a superior effect of effectively inhibiting inflammatory responses by inhibiting the expression of inflammatory cytokines and promoting the expression of anti-inflammatory factors. Therefore, the composition can be effectively used for preventing or treating an inflammatory disease.

Abstract: A composition suitable for diagnosing a musculoskeletal disease and a composition suitable for preventing or treating a musculoskeletal disease are disclosed. The composition contains zinc finger protein with KRAB and SCAN domains 8 (Zkscan8) protein, which can be effectively used as an excellent biomarker for obtaining accurate information about the occurrence and progression stages of a musculoskeletal disease, specifically a tendon disease or a ligament disease. The compositions containing Zkscan8 can be effectively used for preventing or treating a musculoskeletal disease through Zkscan8 overexpression.

Abstract: A multilayer electronic component includes: a body including dielectric layers and internal electrodes alternately stacked with one of the dielectric layers interposed therebetween; and external electrodes disposed on external surfaces of the body and connected to the internal electrodes. One of the internal electrodes includes a plurality of conductive particles and conductive nanowires each of which having a shape different from a shape of the plurality of conductive particles and being connected to at least one of the plurality of conductive particles.

Abstract: A multilayer capacitor includes a capacitor body having first to sixth surfaces, including a plurality of first and second dielectric layers and a plurality of internal electrodes stacked; and first and second external electrodes. The internal electrode includes first and second internal electrodes, a first floating electrode disposed between the first and second internal electrodes on the first dielectric layer, and second and third floating electrodes disposed on the second dielectric layer. The second floating electrode overlaps a portion of the first internal electrode and a portion of the first floating electrode, and the third floating electrode overlaps a portion of the second internal electrode and a portion of the first floating electrode. a/L is 0.113 or more, in which L is a length of the capacitor body, and a is a distance between the first floating electrode and the first or second internal electrodes.

Abstract: A multilayer electronic component includes: a body including dielectric layers and internal electrodes alternately stacked with one of the dielectric layers interposed therebetween; and external electrodes disposed on external surfaces of the body and connected to the internal electrodes. One of the internal electrodes includes a plurality of conductive particles and conductive nanowires each of which having a shape different from a shape of the plurality of conductive particles and being connected to at least one of the plurality of conductive particles.

Abstract: A vacuum cleaner includes a fan motor configured to generate suction, an input button configured to receive an input of a user, a first power supply circuit configured to convert alternating current (AC) power supplied from an external power source and output first direct current (DC) power, a second power supply circuit configured to store electric energy upon receiving the first DC power, and output second DC power based on the stored electric energy, a driver circuit configured to drive the fan motor upon receiving at least one of the first DC power and the second DC power, a first semiconductor switching circuit configured to control the first DC power supplied to the second power supply circuit, a second semiconductor switching circuit configured to control the first DC power and the second DC power that are supplied to the driver circuit, and a microprocessor configured to output a control signal for turning on or off the first semiconductor switching circuit and the second semiconductor switching circu

Abstract: The present invention relates to a method for isolating umbilical cord-derived stem cells, and more specifically to a method for isolating a significantly large number of mesenchymal stem cells from the umbilical cord having a specified size. The method of the present invention has a great advantage in that since stem cells can be isolated from an umbilical cord tissue without enzymatic treatment, stress applied to the cells can be significantly suppressed. In addition, stem cells obtained by the method of the present invention have superior proliferative capacity compared to stem cells obtained by conventional isolation methods.

Abstract: Provided are SUMO activators, which can enhance SUMOylation of SERCA2a, which are useful in the treatment of heart failure, cardiovascular diseases, cancer, neurodegenerative disorders, viral infection, bacterial infection, liver disease, inflammation, and other diseases.

Abstract: Methods for treating cardiovascular disease, and in particular heart failure, are provided comprising administering a therapeutically effective amount of a modulator of SERCA2a post-translation modification such as SUMOylation or acetylation. Also provided are methods of treating cardiovascular disease by inhibiting SERCA2a degradation. Further provided are methods of diagnosing a propensity to develop heart failure comprising determining if a SERCA2a mutant is present or determining the level of expression of SUMO1 in cardiomyocytes. The disclosure also provides methods of screening for therapeutics that modulate the post-translational modification of SERCA2a, such as by modulating post-translational SUMOylation and/or acetylation.

Abstract: A vacuum cleaner includes a fan motor configured to generate suction, an input button configured to receive an input of a user, a first power supply circuit configured to convert alternating current (AC) power supplied from an external power source and output first direct current (DC) power, a second power supply circuit configured to store electric energy upon receiving the first DC power, and output second DC power based on the stored electric energy, a driver circuit configured to drive the fan motor upon receiving at least one of the first DC power and the second DC power, a first semiconductor switching circuit configured to control the first DC power supplied to the second power supply circuit, a second semiconductor switching circuit configured to control the first DC power and the second DC power that are supplied to the driver circuit, and a microprocessor configured to output a control signal for turning on or off the first semiconductor switching circuit and the second semiconductor switching circu

Abstract: Methods for treating cardiovascular disease, and in particular heart failure, are provided comprising administering a therapeutically effective amount of a modulator of SERCA2a post-translation modification such as SUMOylation or acetylation. Also provided are methods of treating cardiovascular disease by inhibiting SERCA2a degradation. Further provided are methods of diagnosing a propensity to develop heart failure comprising determining if a SERCA2a mutant is present or determining the level of expression of SUMO1 in cardiomyocytes. The disclosure also provides methods of screening for therapeutics that modulate the post-translational modification of SERCA2a, such as by modulating post-translational SUMOylation and/or acetylation.

Abstract: Provided are SUMO activators, which can enhance SUMOylation of SERCA2a, which are useful in the treatment of heart failure, cardiovascular diseases, cancer, neurodegenerative disorders, viral infection, bacterial infection, liver disease, inflammation, and other diseases.

Abstract: Provided are SUMO activators, which can enhance SUMOylation of SERCA2a, which are useful in the treatment of heart failure, cardiovascular diseases, cancer, neurodegenerative disorders, viral infection, bacterial infection, liver disease, inflammation, and other diseases.

Abstract: Methods for treating cardiovascular disease, and in particular heart failure, are provided comprising administering a therapeutically effective amount of a modulator of SERCA2a post-translation modification such as SUMOylation or acetylation. Also provided are methods of treating cardiovascular disease by inhibiting SERCA2a degradation. Further provided are methods of diagnosing a propensity to develop heart failure comprising determining if a SERCA2a mutant is present or determining the level of expression of SUMO1 in cardiomyocytes. The disclosure also provides methods of screening for therapeutics that modulate the post-translational modification of SERCA2a, such as by modulating post-translational SUMOylation and/or acetylation.

Abstract: Methods for treating cardiovascular disease, and in particular heart failure, are provided comprising administering a therapeutically effective amount of a modulator of SERCA2a post-translation modification such as SUMOylation or acetylation. Also provided are methods of treating cardiovascular disease by inhibiting SERCA2a degradation. Further provided are methods of diagnosing a propensity to develop heart failure comprising determining if a SERCA2a mutant is present or determining the level of expression of SUMO1 in cardiomyocytes. The disclosure also provides methods of screening for therapeutics that modulate the post-translational modification of SERCA2a, such as by modulating post-translational SUMOylation and/or acetylation.